98%
921
2 minutes
20
Nitric oxide synthase (NOS) inhibitors induce chronic lymphocytic leukemia (CLL) cell apoptosis and have potential as CLL therapeutics. We determined the half-maximal concentration (ED(50)) of 22 NOS inhibitors that induced CLL cell death in vitro. There was a direct correlation of the NOS1 (but not NOS2) dissociation constant (K(d)) and the hydrophobicity partitioning coefficient of each NOS inhibitor and its ED(50). NOS inhibitors that bound tightly to CLL cell NOS1 and were hydrophobic potently induced CLL cell death. CLL cell RNA and protein analyses confirmed CLL cell NOS1 expression. Our studies permit the rational selection of NOS inhibitors for testing as CLL therapeutics.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.leukres.2007.11.026 | DOI Listing |
J Pathol Transl Med
September 2025
Department of Pathology and Laboratory Medicine, University of California, Irvine (UCI), Irvine, CA, USA.
Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is a clinically indolent lymphoproliferative disorder characterized by accumulation of mature B-cell lymphocytes. Given the common CD5 co-expression, mantle cell lymphoma (MCL) is one of the most important entities in the differential diagnosis. MCL and CLL/SLL might exhibit overlapping morphologic and immunohistochemical features, making diagnosis particularly difficult in cases of composite lymphomas.
View Article and Find Full Text PDFFront Immunol
September 2025
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
This review explores neutrophils' roles in chronic lymphocytic leukemia (CLL), highlighting their functions within the immune system. While neutrophils are known for fighting infections, their altered behavior in CLL significantly impacts disease progression. This review notes the reduced phagocytic abilities of neutrophils and the increased formation of neutrophil extracellular traps (NETs) in patients with CLL.
View Article and Find Full Text PDFInn Med (Heidelb)
September 2025
Klinik für Innere Medizin - Hämatologie/Onkologie und Palliativmedizin, Ev. Stift St. Martin, Koblenz, Deutschland.
Pure white cell aplasia (PWCA) is a rare hematological condition characterized by the complete absence of granulocytes and myeloid precursor cells in the bone marrow. In this case report, we describe a 76-year-old patient with chronic lymphocytic leukemia (CLL) and cutaneous squamous cell carcinoma of the right upper eyelid who developed PWCA after treatment with the immune checkpoint inhibitor (ICI) cemiplimab. The PWCA is a rare side effect of checkpoint inhibitors.
View Article and Find Full Text PDFBecause frail and patients ≥80 years with CLL are still underrepresented in clinical trials, the CLL-Frail trial aimed to evaluate the efficacy and safety of acalabrutinib in these patients. The primary endpoint was the overall response rate (ORR) after 6 cycles of treatment to test the null hypothesis of ORR ≤ 65%.53 patients were included into the trial and 34 patients are still on therapy.
View Article and Find Full Text PDFProc Natl Acad Sci U S A
September 2025
Emory Vaccine Center, Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA 30322.
Chronic lymphocytic leukemia (CLL) remains incurable despite treatment advances, and a major challenge is that biomarkers that predict response and resistance to current therapies are lacking. We report that activated and proliferating malignant CLL B cells in circulation express PD-1, a protein normally expressed in T cells. PD-1 expression is absent in circulating B cells from healthy controls and nonmalignant B cells from patients with CLL.
View Article and Find Full Text PDF